New Delhi: “MSD Pharmaceuticals, a wholly- owned subsidiary of Merck & Co, plans to launch vaccines for Chicken pox, Hepitatis A, Rotavirus and Zoster in the next two-three years,” a top official of the company said.
“Presently, MSD has two products in the vaccines segment and in the next 2-3 years, we plan to bring four more products from our global product portfolio to take the total number to six in the country,” MSD Pharmaceuticals India Managing Director Naveen A Rao said.
The company launched its cervical cancer vaccine under the brand ‘GARDASIL´.
After launching all its products in the next 2-3 years, the company expects to be the number one player in Rs1,000 crore domestic vaccine market by 2013.
“As all these activities would start yielding results in due course of time, we expect to become number one player in the segment by 2013,” Rao said.
Speaking about the company’s plan for GARDASIL, Rao said that MSD would involve physicians and medical institutes for marketing the vaccines in the Indian market.
The company, however, said that it would confine itself to those products having intellectual property rights and has no plans to enter into the generic segment.